38 results about "Immunological diseases" patented technology

A compound represented by general formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a use thereof in treating diseases such as tumors, immunological diseases, and inflammatory diseases, as well as a pharmaceutical preparation and a pharmaceutical composition of the compound, and a use thereof.

The present invention provides a novel multi-strain probiotic formulation and relates to the use of the multi-strain formulation in therapy, in particular for the treatment or prevention of immunological or allergic diseases / disorders, such as allergic rhinitis or allergic conjunctivitis. In addition, the present invention also provides a novel therapeutic regimen that is easy to follow using the probiotic formulations provided herein.

Provided is a novel camptothecin derivative or a conjugate thereof, and a preparation method therefor and an application thereof in medicine. Specifically, provided is a compound represented by general formula (A) or a ligand-drug conjugate thereof, a preparation method therefor, and an application of the ligand-drug conjugate and a pharmaceutical composition thereof in the preparation of a drug for the treatment of cancer or immunological diseases.

The invention relates to the field of medicinal chemistry and medicine, and discloses pentacyclic triterpene derivatives and application thereof in prevention and / or treatment of immune diseases. The pentacyclic triterpene derivative disclosed by the invention has a structure as shown in a formula (I) and has an excellent immunoregulation effect on Tc1, Tc17 and Th17 cells, and the invention also provides application of the compound in preparation of medicines for preventing and / or treating immune diseases.

The invention relates to the technical field of molecular immunology and biology, in particular to a sicca syndrome model mouse B cell immune repertoire sequencing and subpopulation analysis method. The method comprises the following steps: S1, sample preparation: preparing a single-cell suspension from a target autoimmune disease animal model and a preset tissue of a control animal, and carrying out B cell enrichment treatment on the single-cell suspension to obtain a B cell sample; s2, multi-dimensional data parallel analysis: analyzing the B cell sample, and performing parallel construction of the multi-dimensional data; and S3, integrated correlation analysis: carrying out correlation analysis on the immune group library data, the cell subset data and the signal channel data obtained in the step S2 to establish a correlation relationship among specific B cell cloning characteristics, specific B cell subset changes and specific signal channel activity, and carrying out multilevel analysis and generating a B cell immune response mechanism of the autoimmune disease. The efficiency and accuracy of disease mechanism research and drug action mechanism evaluation are remarkably improved.

The invention provides methods for assessing immune system function and status based on cellular analysis. Methods of the present invention involve obtaining mass properties of immune cells collected in a tissue or body fluid sample from a subject. Such mass properties may include the mass of one or more immune cells and / or changes in mass of such immune cells over a period of time. Such data is then used for determining a status of the subject's immune response, and subsequent diagnosis and treatment of an infection or immunological disease or dysfunction.

This invention provides a device for applying ointments for rheumatic and immunological diseases, comprising a box body with an ointment chamber at the top and a buffer chamber inside the box body, the buffer chamber having a flat opening; a control rod rotatably connected to the inner cavity of the buffer chamber, a buffer plate being provided on one side of the control rod, and a first spring connecting the buffer plate and the buffer chamber; a conveyor plate rotatably mounted inside a cylindrical chamber, the conveyor plate having multiple transfer grooves evenly distributed around its circumference; a first tube being provided on the top side of the cylindrical chamber and a second tube being provided on the bottom side; a drive mechanism capable of driving the conveyor plate to rotate. The ointment continuously flowing into the buffer chamber pushes the buffer plate towards the bottom of the buffer chamber, and the first spring also provides an elastic force that pushes the buffer plate upwards. Under the mutual pushing action of the ointment and the buffer plate, the ointment is compressed, reducing gaps and air bubbles, and is discharged from the flat opening, resulting in a uniform and dense ointment without gaps, eliminating the need for secondary coating and repair, and reducing drug waste while ensuring drug absorption.

The present invention relates to novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions. The cells are characterized by a specific marker and activity pattern which distinguishes them from other cells. The invention also provides a process for preparing the immunoregulatory macrophage cells from blood monocytes. In a still further aspect, the invention relates to a pharmaceutical composition comprising the immunoregulatory macrophage cells of the invention or a sub-cellular fraction thereof. A process for preparing a sub-cellular fraction of an immunoregulatory macrophage cell of the invention is also provided.

A pharmaceutical use of a pharmaceutical composition containing platinum drugs or platinum drug co-crystals as main active substances in preventing or treating immunological diseases such as rheumatoid arthritis, and other diseases. The platinum drugs mainly refer to oxaliplatin, and the platinum drug co-crystals mainly refer to carboplatin co-crystals or oxaliplatin co-crystals. Further disclosed is a method using platinum drugs or platinum drug co-crystals, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent.

The application relates to the field of medical devices, in particular to a joint protection device suitable for children with rheumatic and immunological diseases, which comprises a joint protection sleeve, a plurality of first sliding grooves and a plurality of connecting rods are arranged on the two sides of the joint protection sleeve, the first sliding grooves and the connecting rods are in one-to-one correspondence, when the joint protection sleeve wraps the joint, the connecting rods are inserted into the first sliding grooves, and the connecting rods and the first sliding grooves are in sliding cooperation; the adjusting holes and the anti-occlusion mechanisms are communicated in the first sliding grooves, the opening and closing mechanisms are communicated on the communication paths of the adjusting holes and the first sliding grooves, and the opening and closing mechanisms are used for controlling the on-off of the adjusting holes and the first sliding grooves; the anti-occlusion mechanisms are used for connecting the first sliding grooves with the outside based on the negative pressure size in the first sliding grooves. The application can realize dynamic adaptation and intelligent protection, and reduce the occlusion risk caused by rigid fixation of the device.

The invention provides a polypeptide and application thereof in preparation of an immunomodulatory product. It is found that the polypeptide with the amino acid sequence shown as SEQ ID NO: 1 can significantly improve the secretion amount of macrophage inflammatory factors and the ROS generation amount, enhance immunity, significantly reduce the influence of LPS on macrophage NO release and inflammatory factor secretion and repair immune imbalance caused by excessive inflammation, and it is indicated that the polypeptide has excellent immunoregulation activity and can be used for preparing immunomodulatory drugs for treating the macrophage NO release and inflammatory factor secretion. In other words, the polypeptide is suitable for preparing products for enhancing immunity, immunoregulation products and drugs for preventing and / or treating immune diseases.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

The present invention introduces a novel immunotherapeutic approach utilizing dual-targeting cancer cell therapy. This therapy involves dual -targeting constructs that co-express either chimeric antigen receptors (CARs) alone or a CAR with a bispecific T-cell engagers (BiTEs) to target two distinct antigens. This innovative design minimizes antigen escape and enhances cytotoxic efficacy by harnessing the advantages of both CAR-T cells and BiTEs. Additionally, the invention discloses the use of bidirectional or in-line promoters to co-regulate the expression of dual CARs or co-expression of a CAR and a BiTE. It also provides polynucleotide and amino acid sequences for these dual -targeting CAR constructs, with or without BiTEs, for the treatment of B-cell malignancies, autoimmune disorders, and other B cell-related diseases.

The invention relates to the technical field of joint puncture, in particular to an ultrasonic-guided joint puncture device for rheumatism immune disease diagnosis, which comprises a supporting seat, an electric sliding rail is mounted at the lower end of the supporting seat, a first sliding seat slides on the upper surface of the electric sliding rail, and a second sliding seat slides at the upper end of the first sliding seat. The upper surface of the second sliding seat is slidably connected with a positioning ring, two sets of guide buckles are installed at the lower end of the second sliding seat, and sliding rods are slidably arranged in the two sets of guide buckles. The puncture position and the diagnosis position are kept consistent, diagnosis errors or tissue damage risks caused by puncture deviation are reduced, and meanwhile, through scale marks on the outer sides of the two sets of sliding rods, medical staff can visually observe the puncture depth of the puncture needle through the displacement of the two sets of sliding rods in the limiting ring.

The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain and uses thereof. The novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit superior CD8+ T cell activity stimulating capacity and Treg cell inhibitory activity and stimulate and improve anti-tumor immune responses through various mechanisms such as increasing macrophage infiltration in CPS tumors as well as macrophage differentiation and reprogramming into inflammatory phenotype (M1). Thus, the strain and polysaccharides derived from the strain of the present invention can be effectively used for immunomodulation, especially immune boosting, in a subject and can inhibit tumor growth by inducing and enhancing anti-tumor immune responses. The novel strain and polysaccharides derived from the strain of the present invention are useful for preventing, ameliorating or treating various immunological diseases such as tumors, infectious diseases and various immunological diseases caused by or as symptoms of immune dysfunction.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. 20 24 20 45 59 01 J ul 2 02 4 2 0 2 4 2 0 4 5 5 9 0 1 J u l 2 0 2 4

A prodrug platform is useful to deliver pharmaceutically active amines, amides and phenols and their use in the diagnosis, prevention and / or treatment of various diseases. Compared with the parent drug (e.g., Gemcitabine), the prodrugs show a significant overall safety improvement (therapeutic index (TI) improvement), especially in liver. The prodrugs can treat several diseases, including, for example, cancer, metabolic disease, viral infection, immunological disease, neurologic disease, and blood disease.

The invention belongs to the technical field of biological medicine, and discloses a rheumatism immune disease intervention composition based on intestinal flora regulation and application of the composition. Comprising the following components in parts by weight: 10-20 parts of bifidobacterium triple viable bacterium freeze-dried powder, 30-50 parts of a dietary fiber compound, 5-15 parts of a plant extract active component, 2-8 parts of a microelement chelate and 10-30 parts of a pharmaceutically acceptable carrier. According to the composition, the probiotics, the prebiotics and the active ingredients are precisely compounded according to the intestinal flora imbalance characteristic of a patient suffering from the rheumatism immune disease, the composition directly acts on the intestine-liver axis, the immune system function is regulated from the source, and compared with a traditional medicine, the effect target is more precise, and the treatment effect is more remarkable.

Novel Styryl Carboxylate derivative compounds are provided which exhibit activity for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases, and diabetes.

The present invention relates to: novel anti-TIGIT antibodies; and uses thereof for increasing immunity, anticancer treatments, and preventing and / or treating immunological diseases.

The present invention relates to compounds of formula (I) salts and derivatives thereof. Further object of the present invention are compositions, which comprise at least a compound of formula (I) or its pharmaceutically acceptable salts and derivatives, and at least one excipient. Further object of the present invention are compounds of formula (I) or compositions which comprise them, for use in the treatment or prevention of a cancer and / or a metabolic disease and / or an immunological disease. Further object of the present invention is the in vitro use of the compounds as chemical probes.

The invention discloses a TFBG-SPR human immune globulin G sensor based on AuNPs-MXene double sensibilization and with an ultralow detection limit and a detection method of the TFBG-SPR human immune globulin G sensor based on AuNPs-MXene double sensibilization. The broadband light source is sequentially connected with the polarizer and the polarization controller and used for obtaining input light in a P polarization state. An AuNPs-MXene composite double-sensitization interface is sequentially modified and constructed on the surface of a TFBG-SPR sensor plated with a gold film, meanwhile, a goat anti-human IgG antibody is fixed to the composite sensitization interface by means of polydopamine (PDA), and the strength change condition of cladding films on the two sides of a TFBG-SPR nearby area embedded in a micro-fluidic chip is monitored through a spectrum analyzer. Finally, high-sensitivity, high-specificity, extremely-low-concentration (1ng / mL) and wide-range (1ng / mL-100mu g / mL) detection on human IgG is realized, and the detection method provides an effective solution for early instant diagnosis of immune diseases.

To obtain an anti-RepulsiveGuidanceMoleculea (RGMa) antibody which can be used as a medicine for preventing, treating or preventing the recurrence of neurological diseases or immunological diseases, has high binding activity and little side effects.SOLUTION: The problem is solved by providing an isolated RGMa-binding protein which does not inhibit the binding of RGMa to neogenin and neutralizes the neurite outgrowth inhibitory activity of RGMa, preferably an anti-RGMa antibody in which the amino acid sequence of a complementarity-determining region is an amino acid sequence having a specific sequence in the sequence table and SFG.SELECTED DRAWING: Figure 5

Halogenated Benzylidine derivatives which exhibit activity useful for the treatment of immunological diseases and inflammation.

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

Halogenated Benzylidine derivatives which exhibit activity useful for the treatment of immunological diseases and inflammation.

The present application provides anti-IL-13 antibodies and antigen binding fragments thereof. Such antibodies and antigen binding fragments thereof may be used in methods for the treatment and / or prevention of an immunological disease or disorder.

This application relates to the field of data processing technology, and in particular to a method, system, device, medium, and product for generating rheumatoid and immunological test reports. The method includes receiving a VCF file from NGS sequencing, a report output directory, and a report output template to generate an order number; naming the VCF file, patient information file, quality control parameter file, and filter parameter file according to a naming convention including the order number, and saving them to the report output directory; extracting patient information, quality control parameters, filter thresholds, and a list of target rheumatoid and immunological diseases, and combining the paths of relevant files to generate, verify, and save a configuration file containing the order number to the report output directory; starting a Docker container to analyze the VCF file, and automatically filling the analysis results, patient information, and quality control parameters into the report output template, generating and saving a rheumatoid and immunological test report containing the order number to the report output directory, thus achieving fully automated generation and analysis from data input to result output.

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives having Formula I:and / or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and / or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and / or pharmaceutically acceptable salts thereof.